Press Release

Visiongain Ltd.

Global Anti-obesity Drugs Market analysis and Forecast till 2030

April 23rd, 2021 12:00 AM

Visiongain has launched a new pharma report: Global Anti-obesity Drugs Market Forecast 2020-2030: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.

The Global Anti-obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MoA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.

To request a overview of this report please contacts Sara Peerun at or refer to our website:@

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 285-page report you will receive 146 tables and 137 figures– all unavailable elsewhere.

The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Anti-obesity Drugs Market forecast from 2020-2030
  • Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
    • Incretion mimetics/GLP-1 agonists
    • SNDRIs
    • Lipase Inhibitors
    • Serotonin receptor agonists
    • Sympathomimetic-GABA receptor agonists
    • Sympathomimetics
  • Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy:
    • Long-term Drugs
    • Short-term Drugs
  • Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs:
    • Innovator
    • Generic Drugs
  • Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC:
    • Prescription Drugs
    • OTC
  • This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs:
    • Saxenda
    • Contrave/Mysimba
    • Belviq
    • Qysmia
    • Xenical
    • Alli
  • This report provides individual revenue forecasts from 2020-2030 for these regional and national markets:
    • US
    • Japan
    • EU5: Germany, France, Spain, Italy, UK
    • BRIC: Brazil, Russia, China, India
    • RoW

Download a Sample Report with Table of Contents and Figures by clicking here @

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs.

  • Our study discusses the selected leading companiesthat are the major players in the anti-obesity drugs market:
    • Arena Pharmaceuticals
    • AstraZeneca
    • Carmot Therapeutics
    • CohBar
    • Currax Pharmaceuticals LLC
    • Eisai
    • ERX Pharmaceuticals
    • Gelesis
    • GlaxoSmithKline (GSK)
    • Hanmi Pharmaceutical
    • LNC Therapeutics
    • Novartis
    • Novo Nordisk
    • Pfizer
    • Rhythm Pharmaceuticals, Inc.
    • Roche
    • Saniona
    • Scohia Pharma, Inc.
    • Sinil Pharmaceutical Co., Ltd
    • Takeda
    • Teva
    • Vivus
  • This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
  • This report gives an overview of pricing and reimbursementin the US and EU.
  • This report provides aSWOT Analysisof the global anti-obesity drugs market.
  • Key questions answered by this report:
    • How is the anti-obesity drugs market evolving?
    • What is driving and restraining anti-obesity drugs dynamics?
    • How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030?
    • How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to?
    • Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030?
    • How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets?
    • Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
    • How will market shares of the national markets change by 2030 and which nation will lead the market in 2030?
    • Who are the leading players and what are their prospects over the forecast period?
    • How will the sector evolve as alliances form during the period between 2020 and 2030?

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

Find More Other Industry Research Reports by Visiongain:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market research company in Europe, the company comprises over 400+ analysts and consultants, adding more than 1400 market research reports to its vast database each year. These reports offer in-depth analysis on 18 industries worldwide. With the help of an interactive market intelligence platform, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Sara Peerun
Commercial Director
Visiongain Limited
Phone: +44 (0) 20 7549 9987.

Report Source:
Press Release Source:


Follow us

LinkedIn | Facebook | Twitter

Press Release

  • Recent
  • Popular
  • Comments
  • Energy Harvesting Equipment Industry 2026 : Detailed survey of the key competitors and the leading players

    Learn More
  • Electric Vehicles (EV) Industry Detailed Analytical Overview by 2026

    Learn More
  • Electric Two-Wheeler Industry : Future Demand, Industry Analysis & Outlook to 2026

    Learn More
  • Medical Tricorder Market 2020 Analysis Trend, Applications, Industry Chain Structure, Growth, and Forecast

    Learn More
  • Opioid Market Development Trends, Revenue and In-Depth Analysis with Specifications

    Learn More
  • Glaucoma Market Business Strategy and Industry Segments Poised for Strong Growth in Future 2028

    Learn More
  • Medical Tricorder Market 2020 Analysis Trend, Applications, Industry Chain Structure, Growth, and Forecast

    Learn More
  • Energy Harvesting Equipment Industry 2026 : Detailed survey of the key competitors and the leading players

    Learn More